Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FullHope Biomedical Co's Other Operating Expense for the
six
months ended in Dec. 2025 was NT$-0.00 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-0.00 Mil.
FullHope Biomedical Co's quarterly Other Operating Expense
declined
from Dec. 2024 (NT$-0.00 Mil) to Jun. 2025 (NT$-0.00 Mil) and
declined
from Jun. 2025 (NT$-0.00 Mil) to Dec. 2025 (NT$-0.00 Mil).
FullHope Biomedical Co's annual Other Operating Expense
increased
from Dec. 2023 (NT$-0.00 Mil) to Dec. 2024 (NT$0.00 Mil) but then
declined
from Dec. 2024 (NT$0.00 Mil) to Dec. 2025 (NT$-0.00 Mil).
FullHope Biomedical Co Other Operating Expense Related Terms
FullHope Biomedical Co Other Operating Expense Historical Data
* Premium members only.
The historical data trend for FullHope Biomedical Co's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FullHope Biomedical Co Other Operating Expense Chart
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of NT$-0.00 Mil mean?
FullHope Biomedical Co (ROCO:7773) has a Other Operating Expense of NT$-0.00 Mil as of Dec. 2025. Other operating expenses that a company records on its income statement. View historical data on FullHope Biomedical Co and its competitors.
Is FullHope Biomedical Co's Other Operating Expense too high?
FullHope Biomedical Co's current Other Operating Expense is NT$-0.00 Mil. Overall, FullHope Biomedical Co has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does FullHope Biomedical Co's Other Operating Expense compare to VRTX and REGN?
FullHope Biomedical Co's Other Operating Expense of NT$-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on FullHope Biomedical Co and its competitors. FullHope Biomedical Co's current Other Operating Expense is NT$-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is FullHope Biomedical Co stock overvalued right now?
FullHope Biomedical Co (ROCO:7773) has a current Other Operating Expense of NT$-0.00 Mil. The current Other Operating Expense is NT$-0.00 Mil. FullHope Biomedical Co's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For FullHope Biomedical Co (ROCO:7773), the current Other Operating Expense is NT$-0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
FullHope Biomedical Co Ltd focuses on immune system-related services and innovative R&D. It establishes cell-based immunotherapies for cancers and autoimmune disorders. Its services are, Immunoprofiling, Circulating Tumor Cells Testing, Regulation of Cell Therapy, Contracting Immune Cell Manufacturing, Immune Cell Bank, Contract Research Organization, and Endotoxin and Mycoplasma Detection Service.
12GF Score
Get the complete analysis for ROCO:7773
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7773 has been successfully added to your 
